Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.47 |
| ▸ | PGK1 | P00558 | 1/20 | 0.47 |
| ▸ | PGK2 | P07205 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1274810 | 1.00 | ADORA3 (0.51) | ADORA3ADORA1KDM4EPKMCYP2C19 | |
| SCHEMBL1274809 | 1.00 | ADORA3 (0.51) | ADORA3ADORA1KDM4EPKMCYP2C19 | |
| SCHEMBL29389281 | 1.00 | ADORA3 (0.51) | ADORA3ADORA1KDM4EPKMCYP2C19 | |
| SCHEMBL28894185 | 0.93 | ADORA3 (0.54) | ADORA3ADORA1KDM4EPKMCYP2C19 | |
| SCHEMBL28894183 | 0.93 | ADORA3 (0.54) | ADORA3ADORA1KDM4EPKMCYP2C19 | |
| SCHEMBL17984828 | 0.90 | ADORA2A (0.47) | — | |
| SCHEMBL28671616 | 0.89 | ADORA3 (0.52) | ADORA3ADORA1KDM4EPKMCYP2C19 | |
| SCHEMBL28671612 | 0.89 | ADORA3 (0.52) | ADORA3ADORA1KDM4EPKMCYP2C19 | |
| SCHEMBL63913 | 0.86 | KDM4E (0.51) | ADORA3ADORA1KDM4EPKM | |
| SCHEMBL63914 | 0.86 | KDM4E (0.51) | ADORA3ADORA1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1092 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382669-A1 | METHOD FOR ANALYZING MODIFIED NUCLEOSIDE | SHIMADZU CORPORATION (JP) | 2025-12-18 | — | — | US | claimed |
| US-20250325494-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-10-23 | — | — | US | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250188013-A1 | LIPID COMPOUND AND USE THEREOF | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-06-12 | — | — | US | claimed |
| EP-4565692-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| EP-4008334-B1 | MANNOSE-BASED MRNA TARGETED DELIVERY SYSTEM AND USE THEREOF | SHENZHEN RHEGEN BIOTECHNOLOGY CO LTD (CN) | 2024-12-04 | — | — | EP | claimed |
| US-20240285795-A1 | TARGETS FOR RNA THERAPEUTICS | CureVac SE (DE) | 2024-08-29 | — | — | US | claimed |
| EP-4393484-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | claimed |
| EP-4393511-A1 | LIPID COMPOUND AND USE THEREOF | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024012272-A1 | LIPID COMPOUND AND USE THEREOF | 传信生物医药(苏州)有限公司 | 2024-01-18 | — | — | WO | claimed |
| WO-2023215498-A2 | COMPOSITIONS AND METHODS FOR CD28 ANTAGONISM | MODERNATX, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| US-11707528-B2 | Mannose-based mRNA targeted delivery system and use thereof | SHENZHEN RHEGEN BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-25 | — | — | US | claimed |
| EP-4008334-A1 | MANNOSE-BASED MRNA TARGETED DELIVERY SYSTEM AND USE THEREOF | Shenzhen Rhegen Biomedical Technology Co., Ltd. (CN) | 2022-06-08 | — | — | EP | claimed |
| US-20220118099-A1 | Mannose-Based mRNA Targeted Delivery System and Use Thereof | SHENZHEN RHEGEN BIOTECHNOLOGY CO., LTD. (CN) | 2022-04-21 | — | — | US | claimed |
| WO-2022000884-A1 | MANNOSE-BASED MRNA TARGETED DELIVERY SYSTEM AND USE THEREOF | 深圳市瑞吉生物科技有限公司 | 2022-01-06 | — | — | WO | claimed |
| US-20180126003-A1 | NEW TARGETS FOR RNA THERAPEUTICS | CureVac SE (DE) | 2018-05-10 | — | — | US | claimed |
| EP-2201118-B1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRANA DISCOVERY (US) | 2012-04-18 | — | — | EP | claimed |
| EP-2201118-A2 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | Trana Discovery (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009036299-A2 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION | TRANA DISCOVERY (US) | 2009-03-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325494-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | FABP1, POLRMT, LIPC | ADORA3 2239/4885ADORA1 2553/4885KDM4E 4795/4885 |
| US-20250188013-A1 | LIPID COMPOUND AND USE THEREOF | NPC1L1, CYP46A1, PCSK9 | ADORA3 3881/4885ADORA1 3765/4885KDM4E 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.